Inventor · disambiguated record
Thomas Schrader
Also filed as: SCHRADER THOMAS · SCHRADER THOMAS O
13 granted patents·11 pending applications·26 citations·filing 2003–2025
88Inventor score
Files withARENA PHARM INC7CONTINEUM THERAPEUTICS INC5PIPELINE THERAPEUTICS INC4SCHRADER THOMAS2SEMPLE GRAEME2
Top patents by PatentIndex Score
24 records- 0192US11752149B2Muscarinic acetylcholine M1 receptor antagonistsPIPELINE THERAPEUTICS INC·Filed 2020·Granted Sep 12, 2023·3 cites·2 claims
- 0285US11512090B2Muscarinic acetylcholine M1 receptor antagonistsPIPELINE THERAPEUTICS INC·Filed 2019·Granted Nov 29, 2022·4 cites·19 claims
- 0382US9085581B2Processes for the preparation of S1P1 receptor modulators and crystalline forms thereofJONES ROBERT M·Filed 2011·Granted Jul 21, 2015·6 cites·30 claims
- 0481US10836764B25-HT2C receptor agonists and compositions and methods of useARENA PHARM INC·Filed 2017·Granted Nov 17, 2020·2 cites·39 claims
- 0581US7241792B2Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereofARENA PHARM INC·Filed 2005·Granted Jul 10, 2007·4 cites·62 claims
- 0680US12054487B2Muscarinic acetylcholine M1 receptor antagonistsCONTINEUM THERAPEUTICS INC·Filed 2019·Granted Aug 6, 2024·2 cites·18 claims
- 0774US12390462B2Muscarinic acetylcholine M1 receptor antagonistsCONTINEUM THERAPEUTICS INC·Filed 2023·Granted Aug 19, 2025·0 cites·6 claims
- 0873US7612106B2Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereofARENA PHARM INC·Filed 2006·Granted Nov 3, 2009·1 cites·54 claims
- 0972US2025026758A1Muscarinic acetylcholine m1 receptor antagonistsCONTINEUM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1065US8507473B23H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disordersBOATMAN P DOUGLAS·Filed 2009·Granted Aug 13, 2013·1 cites·26 claims
- 1163US2009258892A1Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereofARENA PHARM INC·Filed 2009·Application pending·0 cites
- 1262US11608339B25-HT2C receptor agonists and compositions and methods of useARENA PHARM INC·Filed 2020·Granted Mar 21, 2023·0 cites·20 claims
- 1358US2025034110A1Lpar1 antagonists and uses thereofPIPELINE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1457US8791092B2Molecular tweezers for the treatment of amyloid-related diseasesBITAN GAL·Filed 2010·Granted Jul 29, 2014·3 cites·13 claims
- 1557US2024217981A1Crystalline compound of muscarinic acetylcholine m1 receptor antagonistsPIPELINE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1657US2025179045A1Lpar1 antagonists and uses thereofCONTINEUM THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1756US2025171455A1Muscarinic acetylcholine m1 receptor antagonistsCONTINEUM THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1851US8637555B2Tetrazole derivatives and methods of treatment of metabolic-related disorders thereofSEMPLE GRAEME·Filed 2004·Granted Jan 28, 2014·0 cites·2 claims
- 1946US2007254903A1Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions ThereofARENA PHARM INC·Filed 2004·Application pending·0 cites
- 2046US2007072924A1Tetrazole derivatives and methods of treatment of metabolic-related disorders thereofSEMPLE GRAEME·Filed 2006·Application pending·0 cites
- 2144US2021122771A1New molecular tweezers against neurological disorders and viral infectionsUNIV CALIFORNIA·Filed 2019·Application pending·0 cites
- 2241US2015284399A1Processes for the preparation of s1p1 receptor modulators and crystalline forms thereofARENA PHARM INC·Filed 2015·Application pending·0 cites
- 2332US2005239808A1Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occurSCHRADER THOMAS·Filed 2003·Application pending·0 cites
- 2420US8481494B2Compounds for the treatment of diseases related to protein misfoldingSCHRADER THOMAS·Filed 2010·Granted Jul 9, 2013·0 cites·18 claims
Join the waitlist — get patent alerts
Get an alert when Thomas Schrader files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →